ArticleInternational journal of nanomedicine2019
Krill Oil-Incorporated Liposomes As An Effective Nanovehicle To Ameliorate The Inflammatory Responses Of DSS-Induced Colitis.
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- Effect of natural environmental changes on Hainan migratory population with hypertension in China and related plasma metabolism features.Scientific reports · 2025Article
- Systemic dysregulation of the gut microenvironment plays a pivotal role in the onset and progression of inflammatory bowel disease.Frontiers in immunology · 2025Review
- Classification of Nanomaterial Drug Delivery Systems for Inflammatory Bowel Disease.International journal of nanomedicine · 2025Review
- Krill Oil and Its Bioactive Components as a Potential Therapy for Inflammatory Bowel Disease: Insights from In Vivo and In Vitro Studies.Biomolecules · 2024Review
- Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.Pharmaceutics · 2024Review
- Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice.Drug delivery · 2023Article
- Protective effect and mechanism insight of purified Antarctic kill phospholipids against mice ulcerative colitis combined with bioinformatics.Natural products and bioprospecting · 2023Article
- Novel drug delivery systems for inflammatory bowel disease.World journal of gastroenterology · 2022Review
- Broad-Spectrum Theranostics and Biomedical Application of Functionalized Nanomaterials.Polymers · 2022Review
- Exploring the Phosphatidylcholine in Inflammatory Bowel Disease: Potential Mechanisms and Therapeutic Interventions.Current pharmaceutical design · 2022Review
- Krill Oil Combined withFoods (Basel, Switzerland) · 2021Article
- Advances in Technologies for Highly Active Omega-3 Fatty Acids from Krill Oil: Clinical Applications.Marine drugs · 2021Review
- Development of a High Internal Phase Emulsion of Antarctic Krill Oil Diluted by Soybean Oil Using Casein as a Co-Emulsifier.Foods (Basel, Switzerland) · 2021Article
- Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.International journal of nanomedicine · 2021Review
- Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model.Journal of nanobiotechnology · 2020Article
- Natural Product-Based Nanomedicine in Treatment of Inflammatory Bowel Disease.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhosphatidylcholine (PC) and Omega-3 fatty acid (Omega-3) are promising therapeutic molecules for treating inflammatory bowel disease (IBD). PURPOSE: Based on the IBD therapeutic potential of nanoparticles, we herein sought to develop Omega-3-incorporated PC nanoparticles (liposomes) as an orally administrable vehicle for treating IBD.
methodsLiposomes prepared with or without Omega-3 incorporation were compared in terms of colloidal stability and anitiinflammatory effects.
resultsThe incorporation of free Omega-3 (alpha-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid) into liposomes induced time-dependent membrane fusion, resulting in particle size increase from nm to μm during storage. In contrast, krill oil incorporation into liposomes (KO liposomes) did not induce the fusion and the particle size maintained <250 nm during storage. KO liposomes also maintained colloidal stability in simulated gastrointestinal conditions and exhibited a high capacity to entrap the IBD drug, budesonide (BDS). KO liposomes greatly suppressed the lipopolysaccharide-induced production of pro-inflammatory cytokines in cultured macrophages and completely restored inflammation-impaired membrane barrier function in an intestinal barrier model. In mice subjected to dextran sulfate sodium-induced colitis, oral administration of BDS-entrapped KO liposomes suppressed tumor necrosis factor-α production (by 84.1%), interleukin-6 production (by 35.3%), and the systemic level of endotoxin (by 96.8%), and slightly reduced the macroscopic signs of the disease.
conclusionTaken together, KO liposomes may have great potential as a nanovehicle for oral delivery of IBD drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.